PG12 WORK PRODUCTIVITY IN PRIMARY CARE PATIENTS CONSULTING WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS: ESTIMATES FROM THE DANISH RESPONSE STUDY  by Malmberg, I et al.
A346 Paris Abstracts
for the propensity score this remained signiﬁcantly higher (HR  2.93, 95% CI 1.42, 
6.02) for those with concurrent aspirin, but was non-signiﬁcant in those with no 
concurrent aspirin (HR  1.48, 95% CI 0.76, 2.89). In contrast, in the SCCS the rela-
tive incidence (RI) of GI hospitalisation for COX-2 s vs tNSAIDs was 0.73 (0.604, 
0.998) in those with no concurrent ulcer healing drugs. CONCLUSIONS: Traditional 
cohort analysis methods only weakly adjust for confounding, especially confounding 
by indication. Case-only designs give results more akin to trials. Interpretation still 
requires care as each design makes crucial assumptions.
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OBJECTIVES: To estimate work productivity in Danish patients consulting primary 
care physicians with upper gastrointestinal (UGI) symptoms and the effect of acid-
suppressive therapy. METHODS: The RESPONSE study was a randomized, double-
blind, placebo-controlled primary care study focusing on proton pump inhibitor 
treatment of acid-related UGI symptoms. A secondary objective assessed improvement 
in productivity loss following 2 weeks of esomeprazole 40 mg once daily or placebo. 
Work productivity due to UGI symptoms was measured using the Work Productivity 
and Activity Impairment questionnaire speciﬁc for patients with UGI symptoms 
(WPAI : UGIS) and a Danish national average wage rate was applied to calculate the 
value of lost time. Treatment effect on work productivity loss was tested using 
Kolgomorov-Smirnov test. RESULTS: A total of 805 patients completed the study; 
423 patients reported being employed at baseline and were included in the analysis. 
The estimated total cost of average work productivity loss in the 7 days preceding 
contact with the physician was a316 (DKK 2355) per patient (95% conﬁdence interval 
[CI]: a277, a355). This was equivalent to 10.5 working hours/week, and increased 
with increasing severity of UGI symptoms at baseline. Of the total loss, absence from 
work contributed 2.2 hours/week (95% CI: 1.6, 2.8) and reduced productivity while 
at work (presenteeism) 8.3 hours/week (95% CI: 7.3, 9.3). After 2 weeks of treatment, 
the mean improvement in work productivity per week was signiﬁcantly higher for 
both absenteeism (1 hour vs. 0.1 hour, p  0.05) and presenteeism (5.3 hours vs. 4.3 
hours, p  0.05) in patients treated with esomeprazole vs placebo. The economic value 
of the incremental gain in productivity with esomeprazole vs. placebo was a45/week. 
CONCLUSIONS: The results indicate that acid-related UGI symptoms in Danish 
primary care patients represent a signiﬁcant economic burden in terms of lost produc-
tivity, which can be addressed with acid-suppressive therapy. Supported by AstraZen-
eca, Albertslund, Denmark.
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OBJECTIVES: To evaluate the efﬁcacy of iv PPIs in treating PUB. METHODS: 
 Randomised controlled trials (RCTs) identiﬁed in a Cochrane systematic review of 
CENTRAL, EMBASE and MEDLINE (1996 to November 2004) were supplemented 
with an update to December 2008 and then searched for RCTs with consistent pre-
randomization endoscopic haemostatic treatment (EHT) that compared any iv PPI 
with either placebo (including no treatment) or a histamine-2-receptor antagonist 
(H2RA). Data on overall mortality, rebleeding, emergency surgery and further EHT 
were extracted and re-analysed if not analysed by intention-to-treat. Summary effect 
estimates (Relative Risk, RR) were calculated by meta-analysis using a ﬁxed-effects 
model by the Mantel-Haenszel method. Quality of RCTs included in the meta-analysis 
was judged based on an assessment of the method of randomisation and concealment 
of allocation. Sensitivity analysis was conducted using the DerSimonian and Laird 
random-effects model. RESULTS: Of the 251 papers identiﬁed, 10 were suitable to 
provide data for analysis (4 PPI vs H2RA; 6 PPI vs placebo). When compared with 
either an H2RA or placebo, PPIs signiﬁcantly reduced rebleeding (RR 0.53; 95% 
Conﬁdence Interval [CI]: 0.41–0.68; p  0.00001), emergency surgery (RR 0.58; 
95%CI: 0.43–0.79; p  0.0004) and further EHT (RR 0.49; 95%CI: 0.38–0.64; 
p  0.00001). There was a non-signiﬁcant reduction in overall mortality (RR 0.85; 
95%CI: 0.59–1.21; p  0.35), which became signiﬁcant when a single outlier trial was 
excluded in a post-hoc analysis (RR 0.68; 95%CI: 0.46–0.99; p  0.05). The trial 
was excluded based on imbalanced patient allocation: substantially more patients with 
previous PUB were randomised to the placebo arm, and surviving a prior PUB is 
associated with increased likelihood of surviving a subsequent PUB. The sensitivity 
analysis using a random-effects model provided results consistent with the primary 
analysis. CONCLUSIONS: Intravenous PPIs have signiﬁcant beneﬁts over treatment 
with an H2RA or placebo for PUB, which may include a signiﬁcant reduction in overall 
mortality.
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OBJECTIVES: To determine the clinical effectiveness of three anti-TNF-A agents 
(inﬂiximab, adalimumab, etanercept) in refractory Crohn’s dissease (CD). METHODS: 
An electronic literature search was conducted to identify randomized controlled trials 
(RCT) and observational studies on CD and anti-TNF-a drugs that were published 
from 1996–2008 using Medline, EMBASE, PubMed, Wiley’s Cochrane Library, and 
Thomson’s BIOSIS Previews. Websites of professional associations were also searched. 
A random effect pooled analysis was performed when tw0 or more comparable stuides 
were identiﬁed. RESULTS: Of 2557 citations identiﬁed, the publications related to 13 
RCTs and 7 observational studies met the inclusion criteria. All included RCTs had 
a methodological quality score (Jadad scale) of 3 or more. Included effectiveness trials 
were largely placebo-controlled. Findings indicate that inﬂiximab is effective in induc-
tion and maintenance of clinical response and remission in patients with luminal or 
ﬁstulizing CD who are resistant or refractory to conventional therapy. Inﬂiximab also 
reduces the need for surgical resection and hospitalization in CD. Adalimumab was 
shown to be effective for inducing and maintaining clinical remission in CD patients 
with secondary non-response to inﬂiximab or who are naive to anti-TNF-A drugs. No 
statistically signiﬁcant difference was observed between adalimumab and placebo in 
terms of ﬁstula improvement or remission rates. However, a signiﬁcantly higher rate 
of ﬁstula remission was reported when adalimumab was used as maintenance therapy 
in one study. A majority of CD patients re-established reduced response after inﬂix-
imab or adalimumab dose escalation. The results of this review showed that CD 
patients with secondary non-response to inﬂiximab could beneﬁt from adalimumab 
therapy. CONCLUSIONS: Inﬂiximab and adalimumab have shown a consistent 
 superiority to placebo in induction and maintenance of clinical remission, as well 
as in reducing the rates of surgery and hospitalization in refractory CD. CD patients 
who begin to lose their response to anti-TNF-A treatment could beneﬁt from dose 
escalation.
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OBJECTIVES: Prucalopride is a selective 5-HT    4 agonist, effective for treatment of 
chronic constipation, as demonstrated in three pivotal phase III trials and a trial in 
elderly patients. The aim of this study was to explore if baseline patient characteristics 
could predict efﬁcacy of prucalopride after four weeks treatment. Two efﬁcacy 
outcome measures were considered: R1) response deﬁned as an increase from baseline 
of q1 point in patient-reported satisfaction with treatment; R2) response deﬁned as 
an average of q3 spontaneous complete bowel movements (SCBM) per week. 
METHODS: Data from four trials were combined (n  1256). Univariate associations 
of baseline characteristics with response were investigated. Stepwise logistic regression 
was used to build a predictive model and classiﬁcation trees analysis (CTA) models 
were constructed on data from a random selection of two-thirds of the patients. The        
predictive value of the constructed model was evaluated on the remaining one-third 
using ROC-curve analysis. RESULTS: Univariate associations identiﬁed 4 covariates 
strongly associated with R1 (satisfaction with treatment, abdominal pain, laxative use, 
rectal symptoms) and 10 with R2 (SCBM, CBM, SBM, BM, fewer BM than you like, 
satisfaction with BM frequency and regularity, abdominal symptoms, laxative use, 
frequency of BM in preceding six months). The ﬁnal stepwise logistic regression 
models contained the same baseline covariates, whereas the CTA-models contained 
fewer covariates, but had a comparable predictive value (67% positive predictive 
value, 80% sensitivity and 41% speciﬁcity for R1 and 44% positive predictive value, 
17% sensitivity and 91% speciﬁcity for R2). CONCLUSIONS: Self-reported satisfac-
tion with treatment, symptoms, and laxative use at baseline has meaningful predictive 
value for response to treatment with prucalopride in patients with chronic 
constipation.
GASTROINTESTINAL DISORDERS – Cost Studies
PGI6
EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT 
OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH 
PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN 
PRIVATE PAYER PERSPECTIVE
Bastide P, Pontes DAR, Negri MA
Johnson & Johnson Medical Brasil, Sao Paulo, SP, Brazil
OBJECTIVES: To evaluate the direct costs related to recurrence of inguinal hernia 
repair, in patients who underwent the surgery with PHS versus Polypropylene mesh, 
under the Brazilian private payer perspective. METHODS: A decision model was 
developed to assess the costs and resource usage for the recurrence of inguinal hernia 
repair with the PHS versus Polypropylene mesh under the private payer perspective, 
